Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Heron Therapeutics, Inc./ 8-K

Current Report · Items 2.02, 9.01 · 8-K

Heron Therapeutics, Inc.

HRTXNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, Heron Therapeutics, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2026 (“Earnings Press Release”). A copy of the Earnings Press Release is furnished as Exhibit 99.1.…

Filed Aug 10, 2026Accepted Aug 10, 2026, 8:00 AM EDTCIK 818033Accession 0001193125-26-341300
View company →Permanent SEC source ↗
Share

Company context

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Current securities

HRTXNASDAQ · EQUITY · Current

Recent company filings

  1. Entry into a Material Definitive Agreement · Material Modification to Rights of Security HoldersAug 14, 2026
  2. 10-Q filingAug 10, 2026
  3. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingJun 25, 2026
  4. Submission of Matters to a Vote of Security HoldersJun 16, 2026
  5. Other EventsJun 2, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, Heron Therapeutics, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2026 (“Earnings Press Release”). A copy of the Earnings Press Release is furnished as Exhibit 99.1. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) hrtx-ex99_1.htm

EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF® net revenue grew 35% and APONVIE® net revenue grew 74% year-over-year - Amended credit facility with Hercules Capital: financial covenants reset through 2027, and outstanding principal to be reduced by a total potential reduction of $17.5 million - $13.5 million at execution and a potential further reduction of $4 million scheduled on or before September 15, 2026 - Withdrew full-year 2026 financial guidance CARY, N.C., August 10, 2026 (GLOBE NEWSWIRE) - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2026, and highlighted recent corporate updates. “Second quarter revenue grew compared to the first quarter but came in below our expectations,” said Craig Collard, Chief Executive Officer of Heron. “What we did over the past ninety days matters more: we reset our balance sheet, tightened our spending, and we are considering strateg…

Open exhibit ↗